EMAIL THIS PAGE TO A FRIEND

The Veterinary clinics of North America. Small animal practice

NIDDM in the cat: treatment with the oral hypoglycemic medication, glipizide.


PMID 7660535

Abstract

The oral hypoglycemic medication, glipizide, provides a viable therapeutic alternative to conventional insulin therapy with a positive therapeutic response in approximately 50% of diabetic cats with non-insulin-dependent disease. Response to glipizide therapy or lack thereof usually is evident within the first 4 to 6 weeks of treatment. Adverse side effects occurred in less than 10% of patients. The existence of residual beta cell function is necessary for response to glipizide therapy. Predictors of response to glipizide therapy were not found. Identification and correction or control of existing insulin antagonistic disease processes, as well as, discontinuation of diabetogenic medications that may be contributing to insulin resistance is also important.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

G0340000
Glipizide, European Pharmacopoeia (EP) Reference Standard
C21H27N5O4S